• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Reneo Pharmaceuticals Inc. (Amendment)

    5/30/23 4:52:51 PM ET
    $RPHM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPHM alert in real time by email
    SC 13D/A 1 d499424dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    RENEO PHARMACEUTICALS, INC.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    75974E103

    (CUSIP Number)

    Jay W. Schmelter

    101 S. Hanley Road, Suite 1850

    St. Louis, MO 63105

    (314) 726-6700

    With copy to:

    Gloria M. Skigen, Esq.

    Holland & Knight LLP

    One Stamford Plaza 263 Tresser Boulevard Suite 1400

    Stamford, CT 06901

    (203) 905-4526

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 8, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Fund III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      328,094

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      328,094

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      328,094

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.97%(1)

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    The percentage set forth in row (13) is based on 33,655,123 shares of common stock, par value $0.0001 per share, of Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), outstanding as of May 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with Securities and Exchange Commission (“SEC”) on May 11, 2023.

     

    2


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Fund III (Ohio), L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      17,413

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      17,413

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,413

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.05%(1)

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    3


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Partners III (Ohio), LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      17,413(2)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      17,413(2)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,413(2)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.05%(1)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (2)

    Represents 17,413 shares of Common Stock owned by RiverVest Venture Fund III (Ohio), L.P., a Delaware limited partnership (“RiverVest III (Ohio)”). RiverVest Venture Partners III (Ohio), LLC, a Delaware limited liability company (“RiverVest Partners III (Ohio)”), is the general partner of RiverVest III (Ohio).

     

    4


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Partners III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      345,507(3)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      345,507(3)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      345,507(3)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      1.03%(1)

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (3)

    Represents 328,094 shares of Common Stock owned by RiverVest Venture Fund III, L.P., a Delaware limited partnership (“RiverVest III”), and 17,413 shares of Common Stock owned by RiverVest III (Ohio). RiverVest Venture Partners III, L.P., a Delaware limited partnership (“RiverVest Partners III”), is the general partner of RiverVest III and the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

     

    5


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Partners III, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      345,507(4)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      345,507(4)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      345,507(4)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      1.03%(1)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (4)

    Represents 328,094 shares of Common Stock owned by RiverVest III and 17,413 shares of Common Stock owned by RiverVest III (Ohio). RiverVest Venture Partners III, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners III, which is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

     

    6


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Fund IV, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      2,188,713

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      2,188,713

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,188,713

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.50%(1)

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    7


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Partners IV, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      2,188,713(5)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      2,188,713(5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,188,713(5)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.50%(1)

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (5)

    Represents 2,188,713 shares of Common Stock owned by RiverVest Venture Fund IV, L.P., a Delaware limited partnership (“RiverVest IV”). RiverVest Venture Partners IV, L.P., a Delaware limited partnership (“RiverVest Partners IV”), is the general partner of RiverVest IV.

     

    8


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      RiverVest Venture Partners IV, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      2,188,713(6)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      2,188,713(6)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,188,713(6)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.50%(1)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (6)

    Represents 2,188,713 shares of Common Stock owned by RiverVest IV. RiverVest Venture Partners IV, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners IV, which is the general partner of RiverVest IV.

     

    9


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      John P. McKearn, Ph.D.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      2,534,220(7)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      2,534,220(7)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,534,220(7)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.53%(1)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (7)

    Includes 328,094 shares of Common Stock owned by RiverVest III, 17,413 shares of Common Stock owned by RiverVest III (Ohio), and 2,188,713 shares of Common Stock owned by RiverVest IV.

    Dr. McKearn is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

    Dr. McKearn is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV.

     

    10


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      Jay Schmelter

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      2,534,220(8)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      2,534,220(8)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,534,220(8)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.53%(1)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (8)

    Includes 328,094 shares of Common Stock owned by RiverVest III, 17,413 shares of Common Stock owned by RiverVest III (Ohio), and 2,188,713 shares of Common Stock owned by RiverVest IV.

    Mr. Schmelter is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

    Mr. Schmelter is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV.

     

    11


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      Thomas C. Melzer

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      345,507(9)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      345,507 (9)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      345,507 (9)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      1.03%(1)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (9)

    Includes 328,094 shares of Common Stock owned by RiverVest III and 17,413 shares of Common Stock owned by RiverVest III (Ohio).

    Mr. Melzer is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

     

    12


      1    

      NAME OF REPORTING PERSON

      I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

      Niall O’Donnell, Ph.D.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      USA

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      130,971(10)

         8   

      SHARED VOTING POWER

     

      2,188,713(11)

         9   

      SOLE DISPOSITIVE POWER

     

      130,971(10)

       10   

      SHARED DISPOSITIVE POWER

     

      2,188,713(11)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,188,713(11)

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☒

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.50%(1)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (10)

    Represents 130,971 shares of Common Stock options owned by Mr. O’Donnell.

    (11)

    Represents 2,188,713 shares of Common Stock owned by RiverVest IV.

    Mr. O’Donnell is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV.

     

    13


    Schedule 13D/A

    Pursuant to Rule 13d-2 of Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended, the undersigned hereby amends the statement on Schedule 13D (the “Schedule 13D”) dated April 19, 2021. This Statement constitutes Amendment No. 1 to the Schedule 13D. Unless otherwise indicated herein, there are no material changes to the information set forth in the Schedule 13D.

    Item 1. Security and Issuer.

    Item 1 of Schedule 13D is hereby amended to replace address of the principal executive office of the Issuer with the following:

    18575 Jamboree Road, Suite 275-S, Irvine, California 92612

    Item 2. Identity and Background.

    No change.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of Schedule 13D is hereby amended and supplemented as follows:

    On May 8, 2023, RiverVest IV purchased 125,000 shares of Common Stock as part of the Issuer’s underwritten public offering of Common Stock on the Issuer’s prospectus filed under Rule 424(b)(5), filed with the SEC on May 4, 2023 and the exercise of the underwriters’ over-allotment in full. RiverVest IV purchased such shares for a total consideration of $1 million. The purchase price for these shares was paid by RiverVest IV from its working capital.

    Item 4. Purpose of the Transaction.

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

    Underwritten Public Offering

    On May 8, 2023, RiverVest IV purchased 125,000 shares of Common Stock as part of the Issuer’s underwritten public offering of Common Stock on the Issuer’s prospectus filed under Rule 424(b)(5), filed with the SEC on May 4, 2023 and the exercise of the underwriters’ over-allotment in full. RiverVest IV purchased such shares for a total consideration of $1 million.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a) and (b)

     

    Entity or Individual    Shares
    Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of
    Class(*)
     

    RiverVest Venture Fund III, L.P.

         328,094        0        328,094        0        328,094        328,094        0.97 % 

    RiverVest Venture Fund III (Ohio), L.P.

         17,413        0        17,413        0        17,413        17,413        0.05 % 

    RiverVest Venture Partners III (Ohio), LLC(1)

         0        0        17,413        0        17,413        17,413        1.03 % 

    RiverVest Venture Partners III, L.P. (2)

         0        0        345,507        0        345,507        345,507        1.03 % 

     

    14


    RiverVest Venture Partners III, LLC(3)

         0        0        345,507        0        345,507        345,507        1.03 % 

    RiverVest Venture Fund IV, L.P.

         2,188,713        0        2,188,713        0        2,188,713        2,188,713        6.50 % 

    RiverVest Venture Partners IV, L.P. (4)

         0        0        2,188,713        0        2,188,713        2,188,713        6.50 %

    RiverVest Venture Partners IV, LLC(5)

         0        0        2,188,713        0        2,188,713        2,188,713        6.50 %

    John P. McKearn, Ph.D.(6)

         0        0        2,534,220        0        2,534,220        2,534,220        7.53 %

    Jay Schmelter(7)

         0        0        2,534,220        0        2,534,220        2,534,220        7.53 %

    Thomas C. Melzer(8)

         0        0        345,507        0        345,507        345,507        1.03 % 

    Niall O’Donnell(9)

         130,971        130,971        2,188,713        130,971        2,188,713        2,188,713        6.50 %

     

    (*)

    Based on 33,655,123 shares of Common Stock outstanding as of May 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with SEC on May 11, 2023

     

    (1)

    RiverVest Partners III (Ohio) is the general partner of RiverVest III (Ohio), and as a result, may be deemed to beneficially own the 17,413 shares of Common Stock owned by RiverVest III (Ohio).

     

    (2)

    RiverVest Partners III is the general partner of RiverVest III and the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio), and as a result, may be deemed to beneficially own the 328,094 shares of Common Stock owned by RiverVest III and the 17,413 shares of Common Stock owned by RiverVest III (Ohio).

     

    (3)

    RiverVest Venture Partners III, LLC is the general partner of RiverVest Partners III, which is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio), and as a result, may be deemed to beneficially own the 328,094 shares of Common Stock owned by RiverVest III and the 17,413 shares of Common Stock owned by RiverVest III (Ohio).

     

    (4)

    RiverVest Partners IV is the general partner of RiverVest IV, and as a result, may be deemed to beneficially own the 2,188,713 shares of Common Stock owned by RiverVest IV.

     

    (5)

    RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV, which is the general partner of RiverVest IV, and as a result, may be deemed to beneficially own the 2,188,713 shares of Common Stock owned by RiverVest IV.

     

    (6)

    Dr. McKearn is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). As a result, Dr. McKearn may be deemed to beneficially own the 328,094 shares of Common Stock owned by RiverVest III and the 17,413 shares of Common Stock owned by RiverVest III (Ohio).

    Dr. McKearn is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV. As a result, Dr. McKearn may be deemed to beneficially own the 2,188,713 shares of Common Stock owned by RiverVest IV.

     

    (7)

    Mr. Schmelter is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). As a result, Mr. Schmelter may be deemed to beneficially own the 328,094 shares of Common Stock owned by RiverVest III and the 17,413 shares of Common Stock owned by RiverVest III (Ohio).

    Mr. Schmelter is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV. As a result, Dr. McKearn may be deemed to beneficially own the 2,188,713 shares of Common Stock owned by RiverVest IV.

     

    (8)

    Mr. Melzer is a member of RiverVest Venture Partners III, LLC, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). As a result, Mr. Melzer may be deemed to beneficially own the 328,094 shares of Common Stock owned by RiverVest III and the 17,413 shares of Common Stock owned by RiverVest III (Ohio).

     

    (9)

    Mr. O’Donnell is a member of RiverVest Venture Partners IV, LLC, which is the general partner of RiverVest Partners IV. RiverVest Partners IV is the general partner of RiverVest IV. As a result, Mr. O’Donnell may be deemed to beneficially own the 2,188,713 shares of Common Stock owned by RiverVest IV.

     

    15


    By virtue of the relationships described herein, the Reporting Persons may be deemed to constitute a “group” for purposes of Section 13(d)(3) of the Act. The filing of this Statement shall not be construed as an admission that the Reporting Persons are a group, or have agreed to act as a group. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein, except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities.

    (c) Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

    (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    No change.

    Item 7. Material to be Filed as Exhibits.

    No change.

     

    16


    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    May 30, 2023

     

    RiverVest Venture Fund III, L.P.     RiverVest Venture Fund III (Ohio), L.P.
    By:   RiverVest Venture Partners III, L.P.,     By:   RiverVest Venture Partners III (Ohio), LLC,
      its general partner       its general partner
    By:   RiverVest Venture Partners III, LLC,     By:   RiverVest Venture Partners III, L.P.,
      its general partner       its sole member
          By:  

    RiverVest Venture Partners III, LLC,

    its general partner

    By:  

    /s/ Jay Schmelter

         
      Name: Jay Schmelter      
      Title: Member     By:  

    /s/ Jay Schmelter

            Name: Jay Schmelter
            Title: Member
    RiverVest Venture Partners III (Ohio), LLC     RiverVest Venture Partners III, L.P.
    By:   RiverVest Venture Partners III, L.P.,     By:   RiverVest Venture Partners III, LLC,
      its sole member       its general partner
    By:   RiverVest Venture Partners III, LLC,      
      its general partner     By:  

    /s/ Jay Schmelter

            Name: Jay Schmelter
    By:  

    /s/ Jay Schmelter

          Title: Member
      Name: Jay Schmelter      
      Title: Member      
    RiverVest Venture Partners III, LLC     RiverVest Venture Fund IV, L.P.
    By:  

    /s/ Jay Schmelter

        By:   RiverVest Venture Partners IV, L.P.,
      Name: Jay Schmelter       its general partner
      Title: Member     By:   RiverVest Venture Partners IV, LLC,
            its general partner
          By:  

    /s/ Jay Schmelter

            Name: Jay Schmelter
            Title: Member
    RiverVest Venture Partners IV, L.P.     RiverVest Venture Partners IV, LLC
    By:   RiverVest Venture Partners IV, LLC,     By:  

    /s/ Jay Schmelter

      its general partner       Name: Jay Schmelter
            Title: Member
    By:  

    /s/ Jay Schmelter

         
      Name: Jay Schmelter      
      Title: Member      

    /s/ John P. McKearn, Ph.D.

       

    /s/ Jay Schmelter

    John P. McKearn, Ph.D.     Jay Schmelter

     

    /s/ Thomas C. Melzer

      

    /s/ Niall O’Donnell, Ph.D.

    Thomas C. Melzer    Niall O’Donnell, Ph.D.

    [Signature Page of Schedule 13D]

     

    17

    Get the next $RPHM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPHM

    DatePrice TargetRatingAnalyst
    12/15/2023Outperform → Market Perform
    Leerink Partners
    12/15/2023Buy → Hold
    Jefferies
    12/15/2023$30.00 → $1.50Buy → Neutral
    H.C. Wainwright
    12/14/2023Buy → Neutral
    Ladenburg Thalmann
    12/14/2023$23.00 → $1.45Buy → Underperform
    BofA Securities
    12/14/2023Outperform → Mkt Perform
    William Blair
    12/14/2023$28.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/14/2023$25.00 → $4.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $RPHM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

      -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 -- Shares to trade on Nasdaq under the new ticker symbol "OKUR" commencing on October 7, 2024 BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR) ("OnKure"), a clinical-stage biopharmaceutical company focused on the develo

      10/4/24 4:57:48 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

      – Combined company to trade on Nasdaq under ticker "OKUR" – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo") today announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo's stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. ("OnKure"). The closing of the merger is anticipated to take place on or around Friday, October 4, 2024. Following the closing of the merger, the combined company plans to change its name from "Reneo Pharmaceut

      10/2/24 8:20:45 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

      IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights On May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the "Merger").The Merger is expected to create a Nasdaq-listed, clinical stage biopharmaceutical company focused on advancing OnKure's portfolio of precision oncology therapies.The Merger a

      8/13/24 7:35:00 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Reneo Pharmaceuticals downgraded by Leerink Partners

      Leerink Partners downgraded Reneo Pharmaceuticals from Outperform to Market Perform

      12/15/23 8:31:56 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals downgraded by Jefferies

      Jefferies downgraded Reneo Pharmaceuticals from Buy to Hold

      12/15/23 8:31:34 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Reneo Pharmaceuticals from Buy to Neutral and set a new price target of $1.50 from $30.00 previously

      12/15/23 6:59:38 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Saccomano Nicholas A was granted 4,556 shares (SEC Form 4)

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      10/8/24 7:29:45 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Phillips Andrew John

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      10/8/24 7:28:32 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mathers Edward T

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      10/8/24 7:27:58 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    SEC Filings

    See more
    • Reneo Pharmaceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)

      10/8/24 5:26:01 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Reneo Pharmaceuticals Inc.

      425 - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)

      10/2/24 5:23:57 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Reneo Pharmaceuticals Inc.

      8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)

      10/2/24 5:20:31 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Reneo Pharmaceuticals Inc.

      SC 13D/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      10/8/24 7:34:57 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reneo Pharmaceuticals Inc.

      SC 13G - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)

      9/26/24 4:00:22 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Reneo Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)

      5/21/24 10:12:24 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Leonard Braden Michael bought $144,738 worth of shares (98,346 units at $1.47) (SEC Form 4)

      4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)

      9/26/24 9:33:44 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $76,237 worth of shares (56,106 units at $1.36) (SEC Form 4)

      4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)

      9/19/24 11:02:54 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $484,344 worth of shares (358,923 units at $1.35) (SEC Form 4)

      4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)

      9/16/24 4:15:23 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Leadership Updates

    Live Leadership Updates

    See more
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

      IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the company's Board of Directors. "Roshawn is an accomplished leader within the biopharma industry," said Mike Grey, Executive Chairman of Reneo Pharmaceuticals. "Her extensive experience in healthcare reimbursement, policy, and patient access will be an invaluable addition to Reneo as we plan for commercialization of REN001 in the U.S. and Europe. We look forward to working with Roshawn o

      8/2/22 7:30:00 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals Announces Changes to its Board of Directors

      IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction with the appointment of Mr. Hoelscher, Kenneth Harrison, Partner at Novo Ventures (US) Inc., resigned from the Reneo Board of Directors. Reneo also today announced that Lon Cardon, Ph.D. will not seek

      1/24/22 8:00:00 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care